Appendix 2A

Application for quotation of +securities

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

If you are an entity incorporated outside Australia and you are seeking quotation of a new class of +securities other than CDIs, you will need to obtain and provide an International Securities Identification Number (ISIN) for that class. Further information on the requirement for the notification of an ISIN is available from the Create Online Forms page. ASX is unable to create the new ISIN for non-Australian issuers.

*Denotes minimum information required for first lodgement of this form, with exceptions provided in specific notes for certain questions. The balance of the information, where applicable, must be provided as soon as reasonably practicable by the entity.

Part 1 – Entity and announcement details

Question no	Question	Answer
1.1	*Name of entity We (the entity here named) apply for +quotation of the following +securities and agree to the matters set out in Appendix 2A of the ASX Listing Rules. ¹	Little Green Pharma Ltd
1.2	*Registration type and number Please supply your ABN, ARSN, ARBN, ACN or another registration type and number (if you supply another registration type, please specify both the type of registration and the registration number).	ABN 44 615 586 215
1.3	*ASX issuer code	LGP
1.4	*This announcement is Tick whichever is applicable.	 A new announcement An update/amendment to a previous announcement A cancellation of a previous announcement
1.4a	*Reason for update Mandatory only if "Update" ticked in Q1.4 above. A reason must be provided for an update.	
1.4b	*Date of previous announcement to this update Mandatory only if "Update" ticked in Q1.4 above.	
1.4c	*Reason for cancellation Mandatory only if "Cancellation" ticked in Q1.4 above.	
1.4d	*Date of previous announcement to this cancellation Mandatory only if "Cancellation" ticked in Q1.4 above.	

¹ Appendix 2A of the Listing Rules includes a warranty that an offer of the securities for sale within 12 months after their issue will not require disclosure under section 707(3) or 1012C(6) of the Corporations Act. If the securities to be quoted have been issued by way of a pro rata offer, to give this warranty, you will generally need to have lodged a cleansing notice with ASX under section 708AA(2)(f) or 1012DAA(2)(f) of the Corporations Act within 24 hours before the securities are offered (see ASIC Regulatory Guide 189 *Disclosure relief for rights issues*). If in doubt, please consult your legal adviser.

1.5

*Date of this announcement

12 March 2021

Part 2 – Type of issue

Question No.	Question	Answer
No. 2.1	*The +securities to be quoted are: Select whichever item is applicable. If you wish to apply for quotation of different types of issues of securities, please complete a separate Appendix 2A for each type of issue.	 Being issued as part of a transaction or transactions previously announced to the market in an Appendix 3B Being issued under a +dividend or distribution plan Being issued as a result of options being exercised or other +convertible securities being converted (a) 1,025,173 fully paid ordinary shares on conversion of:- 381,149 Director Share Rights; and 644,024 Employee Share Rights Unquoted partly paid +securities that have been paid up and are now quoted fully paid +securities +Restricted securities where the escrow period has expired or is about to expire +Securities previously issued under an +employee incentive scheme where the restrictions on transfer have ceased or are about to cease ×Securities issued under an +employee incentive scheme that are not subject to a restriction on transfer or that are to be quoted notwithstanding there is a restriction on transfer (b) 450,140 fully paid ordinary shares
2.2a.1	*Date of Appendix 3B notifying the market of the proposed issue of +securities for which quotation is now being sought	□ Other
	Answer this question if your response to Q2.1 is "Being issued as part of a transaction or transactions previously announced to the market in an Appendix 3B"	
2.2a.2	*Are there any further issues of +securities yet to take place to complete the transaction(s) referred to in the Appendix 3B? Answer this question if your response to Q2.1 is "Being issued as part of a transaction or transactions previously announced to the market in an Appendix 3B".	

2.2a.2.1	*Please provide details of the further issues	
2.20.2.1	of +securities yet to take place to complete the transaction(s) referred to in the Appendix 3B	
	Answer this question if your response to Q2.1 is "Being issued as part of a transaction or transactions previously announced to the market in an Appendix 3B" and your response to Q2.2a.2 is "Yes".	
	Please provide details of the proposed dates and number of securities for the further issues. This may be the case, for example, if the Appendix 3B related to an accelerated pro rata offer with an institutional component being quoted on one date and a retail component being quoted on a later date.	
2.2b.1	*Date of Appendix 3A.1 lodged with ASX in relation to the underlying +dividend or distribution	
	Answer this question if your response to Q2.1 is "Being issued under a dividend or distribution plan".	
2.2b.2	*Does the +dividend or distribution plan meet the requirement of listing rule 7.2 exception 4 that it does not impose a limit on participation?	
	Answer this question if your response to Q2.1 is "Being issued under a dividend or distribution plan".	
	Note: Exception 4 only applies where security holders are able to elect to receive all of their dividend or distribution as securities. For example, Exception 4 would not apply in the following circumstances: 1) The entity has specified a dollar limit on the level of participation e.g. security holders can only participate to a maximum value of \$x in respect of their entitlement, or 2) The entity has specified a maximum number of securities that can participate in the plan e.g. security holders can only receive securities in lieu of dividend payable for x number of securities.	
2.2c.1	Please state the number and type of options that were exercised or other +convertible securities that were converted (including their ASX security code) Answer this question if your response to Q2.1 is "Being issued as a result of options being exercised or other convertible securities being converted".	381,149 Director Share Rights 658,051 Employee Share Rights
2.2c.2	And the date the options were exercised or other +convertible securities were converted Answer this question if your response to Q2.1 is "Being issued as a result of options being exercised or other convertible securities being converted". Note: If this occurred over a range of dates, enter the date the last of the options was exercised or convertible securities was converted.	12 March 2021
2.2d.1	Please state the number and type of partly paid +securities (including their ASX security code) that were fully paid up Answer this question if your response to Q2.1 is "Unquoted partly paid securities that have been paid up and are now quoted fully paid securities".	

2.2d.2	And the date the *securities were fully paid up	
	Answer this question if your response to Q2.1 is "Unquoted partly paid securities that have been paid up and are now quoted fully paid securities".	
	Note: If this occurred over a range of dates, enter the date the last of the securities was fully paid up.	
2.2e.1	Please state the number and type of +restricted securities (including their ASX security code) where the escrow period has expired or is about to expire Answer this question if your response to Q2.1 is "Restricted securities where the escrow period has expired or is about to expire".	
2.2e.2	And the date the escrow restrictions have ceased or will cease	
	Answer this question if your response to Q2.1 is "Restricted securities where the escrow period has expired or is about to expire".	
	Note: If this occurred over a range of dates, enter the date the last of the escrow restrictions has ceased or will cease.	
2.2f.1	Please state the number and type of +securities (including their ASX security code) previously issued under the +employee incentive scheme where the restrictions on transfer have ceased or are about to cease	
	Answer this question if your response to Q2.1 is "Securities previously issued under an employee incentive scheme where the restrictions on transfer have ceased or are about to cease".	
2.2f.2	And the date the restrictions on transfer have ceased or will cease:	
	Answer this question if your response to Q2.1 is "Securities previously issued under an employee incentive scheme where the restrictions on transfer have ceased or are about to cease".	
	Note: If this occurred over a range of dates, enter the date the last of the restrictions on transfer has ceased or will cease.	
2.2g.1	Please state the number and type of +securities (including their ASX security code) issued under an +employee incentive scheme that are not subject to a restriction on transfer or that are to be quoted notwithstanding there is a restriction on transfer	450,140 fully paid ordinary shares
	Answer this question if your response to Q2.1 is "Securities issued under an employee incentive scheme that are not subject to a restriction on transfer or that are to be quoted notwithstanding there is a restriction on transfer".	

2.2g.2	*Please attach a document of details of a URL link for a do with ASX detailing the terms +employee incentive scheme of the terms. Answer this question if your respon "Securities issued under an employ scheme that are not subject to a re- or that are to be quoted notwithstar restriction on transfer".	e or a summary se to Q2.1 is rece incentive striction on transfer		asx.com.au/asx/statistics/displa ent.do?display=pdf&idsId=022
2.2g.3	*Are any of these +securities to +key management persor an +associate Answer this question if your respon "Securities issued under an employ scheme that are not subject to a re- or that are to be quoted notwithstar restriction on transfer".	nnel (KMP) or use to Q2.1 is ree incentive striction on transfer	Yes	
2.2g.3.a	*Provide details of the recipients and the number of +securities issued to each of them. Answer this question if your response to Q2.1 is "Securities issued under an employee incentive scheme that not subject to a restriction on transfer or that are to be quoted notwithstanding there is a restriction on transfer and your response to Q2.2g.3 is "Yes". Repeat the detail in the table below for each KMP involved in the issu the securities are being issued to the KMP, repeat the name of the KMP or insert "Same" in "Name of registe holder". If the securities are being issued to an associate of a KMP, insert the name of the associate in "Name registered holder".			n employee incentive scheme that are ling there is a restriction on transfer" r for each KMP involved in the issue. If r insert "Same" in "Name of registered
	Name of KMP	Name of registered holder		Number of +securities
	Mr Michael David Lynch-Bell	Mr Michael David Lynch-Bell		82,826
	Dr Neale Fong	Dr Neale Fong as trustee for the Damblock Trust		41,413
	Ms Fleta Jennifer Solomon	Ms Fleta Jennifer S	Solomon	40,723
	Mr Angus Caithness	Mr Angus Caithnes	SS	71,782
2.2h.1	*The purpose(s) for which the entity is issuing the +securities is: Answer this question if your response to Q2.1 is "Other". You may select one or more of the items in the list.		 To fund th To pay fo [provide of To pay for [provide of 	additional working capital ne retirement of debt r the acquisition of an asset details below] r services rendered details below] ovide details below] otails:
2.2h.2	*Please provide any further needed to understand the ci which you are applying to ha +securities quoted on ASX, applicable) why the issue of has not been previously ann market in an Appendix 3B You must answer this question if yo Q2.1 is "Other". If there is no other provide, please answer "Not application	rcumstances in ave these including (if the +securities ounced to the our response to information to		

2.2i	*Are these +securities being offered under a +disclosure document or +PDS? Answer this question if your response to Q2.1 is any option other than "Being issued as part of a transaction or transactions previously announced to the market in an Appendix 3B".	No
2.2i.1	*Date of +disclosure document or +PDS? Answer this question if your response to Q2.1 is any option other than "Being issued as part of a transaction or transactions previously announced to the market in an Appendix 3B" and your response to Q2.2i is "Yes". Under the Corporations Act, the entity must apply for quotation of the securities within 7 days of the date of the disclosure document or PDS.	
2.3	*The +securities to be quoted are: <i>Tick whichever is applicable</i>	 Additional +securities in a class that is already quoted on ASX ("existing class") New +securities in a class that is not yet quoted on ASX ("new class")

Part 3A – number and type of +securities to be quoted (existing class or new class) where issue has previously been notified to ASX in an Appendix 3B

Answer the questions in this Part if your response to Q2.1 is "Being issued as part of a transaction or transactions previously announced to the market in an Appendix 3B" and your response to Q2.3 is "existing class" or "new class".

Question No.	Question	Answer
3A.1	*ASX security code & description	
3A.2	*Number of +securities to be quoted	

Part 3B – number and type of +securities to be quoted (existing class) where issue has not previously been notified to ASX in an Appendix 3B

Answer the questions in this Part if your response to Q2.1 is anything other than "Being issued as part of a transaction or transactions previously announced to the market in an Appendix 3B" and your response to Q2.3 is "existing class".

Question No.	Question	Answer
3B.1	*ASX security code & description	LGP fully paid ordinary shares
3B.2	*Number of +securities to be quoted	1,475,313
3B.3a	*Will the +securities to be quoted rank equally in all respects from their issue date with the existing issued +securities in that class?	Yes
3B.3b	*Is the actual date from which the +securities will rank equally (non-ranking end date) known? Answer this question if your response to Q3B.3a is "No".	
3B.3c	*Provide the actual non-ranking end date Answer this question if your response to Q3B.3a is "No" and your response to Q3B.3b is "Yes".	

3B.3d	*Provide the estimated non-ranking end period Answer this question if your response to Q3B.3a is "No" and your response to Q3B.3b is "No".	
3B.3e	*Please state the extent to which the +securities do not rank equally:	
	 in relation to the next dividend, distribution or interest payment; or 	
	 for any other reason 	
	Answer this question if your response to Q3B.3a is "No".	
	For example, the securities may not rank at all, or may rank proportionately based on the percentage of the period in question they have been on issue, for the next dividend, distribution or interest payment; or they may not be entitled to participate in some other event, such as an entitlement issue.	

Part 3C – number and type of +securities to be quoted (new class) where issue has not previously been notified to ASX in an Appendix 3B

DELETED AS NOT APPLICABLE.

Question No.	Question	Answer
4.1	*Have the +securities to be quoted been issued yet?	No
4.1a	*What was their date of issue? Answer this question if your response to Q4.1 is "Yes".	
4.1b	*What is their proposed date of issue? Answer this question if your response to Q4.1 is "No".	12 March 2021
4.2	*Are the +securities to be quoted being issued for a cash consideration? If the securities are being issued for nil cash consideration, answer this question "No".	No
4.2a	*In what currency is the cash consideration being paid For example, if the consideration is being paid in Australian Dollars, state AUD. Answer this question if your response to Q4.2 is "Yes".	
4.2b	*What is the issue price per +security Answer this question if your response to Q4.2 is "Yes" and by reference to the issue currency provided in your response to Q4.2a. Note: you cannot enter a nil amount here. If the securities are being issued for nil cash consideration, answer Q4.2 as "No" and complete Q4.2c and Q4.2d.	

4.2c	Please describe the consideration being provided for the +securities to be quoted <i>Answer this question if your response to Q4.2 is "No".</i>	 (a) issued on conversion of a total of 1,025,173 performance rights, comprising 381,149 Director Share Rights and 644,024 Employee Share Rights which were issued on 17 December 2020 in exchange for salary reduction as previously detailed (b) Issued to Directors and employees in lieu of a discretionary salary reduction at an issue price of \$0.25 per share, comprising:-
		 - 236,744 shares to directors on exercise of share rights (granted and exercised concurrently) on the terms and conditions given in the notice of meeting dated 27 October 2020 and as approved by shareholders on 26 November 2020; - 213,396 shares to employees on exercise of share rights (granted
		and exercised concurrently)
4.2d	Please provide an estimate (in AUD) of the value of the consideration being provided	(a) \$697,118 based on closing share price of \$0.68 on 11 March 2021
	per +security for the +securities to be quoted Answer this question if your response to Q4.2 is "No".	(b) From total salary reduction of \$255,429 during the salary reduction period of 9/11/20 to 01/03/21, comprised of:-
		- \$130,010 from Directors at an average issue price of \$0.55 per share; and
		- \$125,419 from employees at an average issue price of \$0.58 per share
4.3	Any other information the entity wishes to provide about the issue	

Part 5 – Issued capital following quotation

Following the quotation of the +securities the subject of this application, the issued capital of the entity will comprise:

Note: the figures provided in the tables in sections 5.1 and 5.2 below are used to calculate the total market capitalisation of the entity published by ASX from time to time. Please make sure you include in the relevant table each class of securities issued by the entity.

If you have quoted CHESS Depository Interests (CDIs) issued over your securities, include them in the table in section 5.1 and include in the table in section 5.2 any securities that do not have CDIs issued over them (and therefore are not quoted on ASX). Restricted securities should only be included in the table in section 5.1 if you are applying to have them quoted because the escrow period for the securities has expired or is about to expire. Otherwise include them in the table in section 5.2.

5.1	*Quoted +securities (total number of each +class of +securities quoted on ASX following the +quotation of the +securities the subject of this application)		
	ASX security code and description	Total number of +securities on issue	
	LGP fully paid ordinary shares	133,239,912	

5.2	* Unquoted +securities (total number of each +class of +securities issued but not quoted on ASX):		
	ASX security code and description	Total number of +securities on issue	
	Fully paid ordinary shares (subject to escrow)	54,034,703	
	Performance rights	3,000,000	
	Options exercisable at \$0.30, expiring 28/02/22	3,500,000	
	Options exercisable at \$0.48, expiring 31/07/22	2,036,768	
	Options exercisable at \$0.42, expiring 31/07/22	2,036,768	
	Director Retention Share Rights, vesting on 20 February 2023	450,000	
	Management Retention Share Rights, vesting on 20 February 2023	750,000	
	Director Share Rights	75,458	
	Employee Share Rights	159,749	
	L		

Part 6 – Other Listing Rule requirements

The questions in this Part should only be answered if you are an ASX Listing (ASX Foreign Exempt Listings and ASX Debt Listings do not need to complete this Part) and:

Note that if your response to Q2.1 is "Being issued as part of a transaction or transactions previously announced to the market in an Appendix 3B", it is assumed that you will have provided the information referred to in this Part in the Appendix 3B.

Question No.	Question	Answer
6.1	*Has the entity obtained, or is it obtaining, +security holder approval for the issue under listing rule 7.1?	Yes – in respect of 236,744 shares to directors on exercise of share rights (granted and exercised concurrently) on the terms and conditions given in the notice of meeting dated 27 October 2020
6.1a	*Date of meeting or proposed meeting to approve the issue under listing rule 7.1 Answer this question if the response to Q6.1 is "Yes".	Approved by shareholders on 26 November 2020
6.1b	*Are any of the +securities being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1? Answer this question if the response to Q6.1 is "No".	No
6.1b.1	*How many +securities are being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?	
	Answer this question if the response to Q6.1 is "No" and the response to Q6.1b is "Yes".	
	Please complete and separately send by email to your ASX listings adviser a work sheet in the form of Annexure B to Guidance Note 21 confirming the entity	

your response to Q2.1 is "Being issued under a dividend/distribution plan" and the response to Q2.2b.2 is "No"; or
 your response to Q2.1 is "Other".

	has the available capacity under listing rule 7.1 to issue that number of securities.	
6.1c	*Are any of the +securities being issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)? <i>Answer this question if the response to Q6.1 is "No"</i> .	n/a
6.1c.1	*How many +securities are being issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A?	
	Answer this question if the response to Q6.1 is "No" and the response to Q6.1c is "Yes".	
	Please complete and separately send by email to your ASX listings adviser a work sheet in the form of Annexure C to Guidance Note 21 confirming the entity has the available capacity under listing rule 7.1A to issue that number of securities.	

Introduced 01/12/19, amended 31/01/20